Akero
Founded 2017 · 74 employees on LinkedIn · 7 known investors
Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need. The company's lead candidate, efruxifermin, is in phase 3 clinical trials for liver disease treatment.
Investors · 7
Competitors · 2
by search overlapBioworld21 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Robinhood21 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Akero for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Akero do?
- Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need. The company's lead candidate, efruxifermin, is in phase 3 clinical trials for liver disease treatment.
- Who are Akero's investors?
- Akero's investors include Atlas Venture, Foresite Capital, Frazier Life Sciences, Scion Life Sciences, The Innovation Space, venBio Partners, Versant Ventures.